Exogenous interleukin-10 alleviates allergic inflammation but inhibits local interleukin-10 expression in a mouse allergic rhinitis model

BMC Immunology

Ze-Zhang Tao¹  Zheng Liu³  Bo-Kui Xiao¹  Jie Ren¹  Yu-Qin Deng¹  Shui-Bin Wang² 

[1] Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, China;Department of Otolaryngology-Head and Neck Surgery, Hubei University of Science and Technology, Xianning, China;Department of Otolaryngology-Head and Neck Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

关键词: Regulatory T cells;    T-cell subsets;    Mast cells;    Eosinophils;    Interleukin-10;    Allergic rhinitis;   

Others  :  1077725
DOI  :  10.1186/1471-2172-15-9

 received in 2013-07-18, accepted in 2014-02-22,  发布年份 2014

【 摘 要 】

Background

Interleukin-10 (IL-10) has an important anti-inflammatory and immunoregulatory function, and its expression is negatively correlated with the development and severity of allergic rhinitis (AR). However, the in vivo effects of exogenous IL-10 on AR have not been studied and the mechanisms underlying the effects of IL-10 have not been fully understood. Here, we investigated the effects of intranasal administration of recombinant mouse (rm) IL-10 on the expression of Th responses and local IL-10 in a mouse model of AR induced by ovalbumin.

Results

Administration of rmIL-10 during challenge significantly reduced the number of eosinophils and mast cells, as well as Type 2 helper T (Th2) and Th17 cell related cytokine and transcription factor levels in the nasal mucosa and nasal lavage fluid in AR mice. The rmIL-10 treatment significantly inhibited the number of IL-10-positive cells and IL-10 mRNA expression in the nasal mucosa in AR mice.

Conclusion

Our results show that exogenous IL-10 administrated in challenge phase alleviates nasal allergic inflammation in AR mice, most likely by inhibiting Th2 and Th17 responses. It can also inhibit local IL-10 levels in the nasal mucosa. Our findings indicate that IL-10 may have the potential as an inhibitor of AR.

【 授权许可】

   
2014 Wang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Pawankar R, Bunnag C, Khaltaev N, Bousquet J: Allergic rhinitis and its impact on asthma in Asia Pacific and the ARIA update 2008. World Allergy Organ J 2012, 5(Suppl 3):S212-S217. BioMed Central Full Text
• [2]Malmhall C, Bossios A, Pullerits T, Lotvall J: Effects of pollen and nasal glucocorticoid on FOXP3+, GATA-3+ and T-bet + cells in allergic rhinitis. Allergy 2007, 62(9):1007-1013.
• [3]Burgler S, Ouaked N, Bassin C, Basinski TM, Mantel PY, Siegmund K, Meyer N, Akdis CA, Schmidt-Weber CB: Differentiation and functional analysis of human T(H)17 cells. J Allergy Clin Immunol 2009, 123(3):588-595. 595 e581-587
• [4]Ishigame H, Kakuta S, Nagai T, Kadoki M, Nambu A, Komiyama Y, Fujikado N, Tanahashi Y, Akitsu A, Kotaki H, Sudo K, Nakae S, Sasakawa C, Iwakura Y: Differential roles of interleukin-17A and -17 F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 2009, 30(1):108-119.
• [5]Quan SH, Zhang YL, Han DH, Iwakura Y, Rhee CS: Contribution of interleukin 17A to the development and regulation of allergic inflammation in a murine allergic rhinitis model. Ann Allergy Asthma Immunol 2012, 108(5):342-350.
• [6]Lu Y, Malmhall C, Sjostrand M, Radinger M, O’Neil SE, Lotvall J, Bossios A: Expansion of CD4(+) CD25(+) and CD25(−) T-Bet, GATA-3, Foxp3 and RORgammat cells in allergic inflammation, local lung distribution and chemokine gene expression. PLoS One 2011, 6(5):e19889.
• [7]Liu Y, Yu HJ, Wang N, Zhang YN, Huang SK, Cui YH, Liu Z: Clara cell 10-kDa protein inhibits T(H)17 responses through modulating dendritic cells in the setting of allergic rhinitis. J Allergy Clin Immunol 2013, 131(2):387-394. e381-312
• [8]El-Naggar MM, Ukai K, Takeuchi K, Sakakura Y: Expression of interferon-gamma, interleukin-4 and interleukin-5 mRNA in the nasal mucosal membrane of rats with allergic rhinitis. Scand J Immunol 1998, 47(6):554-560.
• [9]Iwasaki M, Saito K, Takemura M, Sekikawa K, Fujii H, Yamada Y, Wada H, Mizuta K, Seishima M, Ito Y: TNF-α contributes to the development of allergic rhinitis in mice. J Allergy Clin Immunol 2003, 112(1):134-140.
• [10]Moore KW, de Waal MR, Coffman RL, O’Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765.
• [11]Ye Z, Huang H, Hao S, Xu S, Yu H, Van Den Hurk S, Xiang J: IL-10 has a distinct immunoregulatory effect on naive and active T cell subsets. J Interferon Cytokine Res 2007, 27(12):1031-1038.
• [12]Amorim CZ, Haile S, Leduc D, Dumarey C, Huerre M, Vargaftig BB, Pretolani M: Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice. J Clin Invest 1995, 95:2644-2651.
• [13]van Scott MR, Paul Justice J, Bradfield JF, Enright E, Sigounas A, Sur S: IL-10 reduces Th2 cytokine production and eosinophilia but augments airway reactivity in allergic mice. Am J Physiol Lung Cell Mol Physiol 2000, 278:667-674.
• [14]Muller B, de Groot EJ, Kortekaas IJ, Fokkens WJ, van Drunen CM: Nasal endothelial interleukin-10 expression is negatively correlated with nasal symptoms after allergen provocation. Allergy 2009, 64(5):738-745.
• [15]Muller B, de Groot EJ, Kortekaas IJ, Fokkens WJ, van Drunen CM: Nasal epithelial cells express IL-10 at levels that negatively correlate with clinical symptoms in patients with house dust mite allergy. Allergy 2007, 62(9):1014-1022.
• [16]Mo JH, Kang EK, Quan SH, Rhee CS, Lee CH, Kim DY: Anti-tumor necrosis factor-alpha treatment reduces allergic responses in an allergic rhinitis mouse model. Allergy 2011, 66(2):279-286.
• [17]Wakashin H, Hirose K, Maezawa Y, Kagami S, Suto A, Watanabe N, Saito Y, Hatano M, Tokuhisa T, Iwakura Y, Puccetti P, Iwamoto I, Nakajima H: IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice. Am J Respir Crit Care Med 2008, 178(10):1023-1032.
• [18]Zhao J, Lloyd CM, Noble A: Th17 responses in chronic allergic airway inflammation abrogate regulatory T-cell-mediated tolerance and contribute to airway remodeling. Mucosal Immunol 2013, 6(2):335-346.
• [19]Cao PP, Li HB, Wang BF, Wang SB, You XJ, Cui YH, Wang DY, Desrosiers M, Liu Z: Distinct immunopathologic characteristics of various types of chronic rhinosinusitis in adult Chinese. J Allergy Clin Immunol 2009, 124(3):478-484. 484 e471-472
• [20]Tang H, Wang H, Bai J, Ding M, Liu W, Xia W, Luo Q, Xu G, Li H, Fang J: Sensitivity of MUC5AC to topical corticosteroid is negatively associated with interleukin-17A in patients with allergic rhinitis. Am J Rhinol Allergy 2012, 26(5):359-364.
• [21]Liu T, Song CH, Liu AM, Xie C, Zhao F, Chen X, Cheng L, Yang PC: Forkhead box P3+ T cells express interleukin-17 in nasal mucosa of patients with both allergic rhinitis and polyposis. Clin Exp Immunol 2011, 163(1):59-64.
• [22]Josefowicz SZ, Niec RE, Kim HY, Treuting P, Chinen T, Zheng Y, Umetsu DT, Rudensky AY: Extrathymically generated regulatory T cells control mucosal TH2 inflammation. Nature 2012, 482(7385):395-399.
• [23]Powrie F, Leach MW, Mauze S, Caddle LB, Coffman RL: Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol 1993, 5(11):1461-1471.
• [24]Foussat A, Cottrez F, Brun V, Fournier N, Breittmayer JP, Groux H: A comparative study between T regulatory type 1 and CD4 + CD25+ T cells in the control of inflammation. J Immunol 2003, 171(10):5018-5026.
• [25]Huang H, Ma Y, Dawicki W, Zhang X, Gordon JR: Comparison of induced versus natural regulatory T cells of the same TCR specificity for induction of tolerance to an environmental antigen. J Immunol 2013, 191(3):1136-1143.
• [26]Gagliani N, Magnani CF, Huber S, Gianolini ME, Pala M, Licona-Limon P, Guo B, Herbert DR, Bulfone A, Trentini F, Di Serio C, Bacchetta R, Andreani M, Brockmann L, Gregori S, Flavell RA, Roncarolo MG: Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. Nat Med 2013, 19(6):739-746.
• [27]Gregori S, Goudy KS, Roncarolo MG: The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. Front Immunol 2012, 3:30.
• [28]Han D, Wang C, Lou W, Gu Y, Wang Y, Zhang L: Allergen-specific IL-10-secreting type I T regulatory cells, but not CD4(+)CD25(+)Foxp3(+) T cells, are decreased in peripheral blood of patients with persistent allergic rhinitis. Clin Immunol 2010, 136(2):292-301.
• [29]Ogawa Y, Duru EA, Ameredes BT: Role of IL-10 in the resolution of airway inflammation. Curr Mol Med 2008, 8(5):437-445.
• [30]Sewerynek E: Current indications for prevention and therapy of steroid-iduced osteoporosis in men and women. Endokrynologia Polska 2011, 62(1):38-44.
• [31]Licata AA: Systemic effects of fluticasone nasal spray: report of 2 cases. Endocr Pract 2005, 11(3):194-196.
• [32]Storms WW: Risk-benefit assessment of fluticasone propionate in the treatment of asthma and allergic rhinitis. J Asthma 1998, 35(4):313-336.
• [33]Wang H, Lu X, Cao PP, Chu Y, Long XB, Zhang XH, You XJ, Cui YH, Liu Z: Histological and immunological observations of bacterial and allergic chronic rhinosinusitis in the mouse. Am J Rhinol 2008, 22(4):343-348.
• [34]Won TB, Quan SH, Rhee CS, Min YG, Lee CH: Expression of uteroglobin in a murine model of allergic rhinitis. Acta Otolaryngol Suppl 2007, 558:83-89.
• [35]Liu Y, Lu X, Yu HJ, Hua XY, Cui YH, Huang SK, Liu Z: The expression of osteopontin and its association with Clara cell 10 kDa protein in allergic rhinitis. Clin Exp Allergy 2010, 40(11):1632-1641.